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ABSTRACT
The optimal treatment for locally advanced rectal cancer 
remains an issue of debate. The surgery with total mesorectal 
excision (TME) still is the standard of care. In contrast to 
TME, the addition of adjuvant or neoadjuvant therapy is 
necessary in terms of local disease control and to increase of 
survival time. Here,  we will review neoadjuvant treatment 
approach in rectal carcinoma.
Keywords: Rectal neoplasms, Neoadjuvant therapy, 
Radiotherapy, Chemotherapy
Introduction
The neoadjuvant treatment has high importance; issue that 
remains controversial is if the radiotherapy should be alone 
or with chemotherapy. Current guidelines recommend 
neoadjuvant treatment included radiotherapy with 
fluorouracil or capecitabine chemotherapy as long-course to 
a total dose 45-50.4 Gy in 1.8-2 Gy fractions or short-course 
to a total dose of 25 Gy in five fractions alone for locally 
advanced rectal cancer. The guidelines also recommend the 
waiting time between neoadjuvant therapy and surgery 6-8 
weeks for long-course and 1-2 weeks for short-course [1, 2]. 
There are two randomized trials of preoperative versus 
postoperative therapy for rectal cancer with conflicting 
results. The German CAO/ARO/AIO 94 trial compared 
preoperative and postoperative chemoradiotherapy and 
resulted with statistical significance for reduced local 
relapse (15%-6%, p: 0.006) in preoperative arm and acute 
toxicity (40%-27%, p:0.001), chronic toxicity (24%-14%, 
p:0.01). There was no significance for overall survival [3]. 
However NSABP R-03 trial did not show any significance 
for local relapse in preoperative arm. The preoperative 
arm had high grade 4 acute toxicity and low grade 3 acute 
toxicity (33%-23%, 41%-50%, respectively). The accrued 
patients number in NSABP trial was lower and statistical 
results were affected negatively [4].
By the most tailored neoadjuvant therapy must be aimed 
that excellent local control, longer survival time and increase 
the sphincter preservation surgery. 
Short-course neoadjuvant radiotherapy
Short-course renders an immediate and intensive therapy 
with hypofractionated radiotherapy schedule. There are a 
lot of trials showed a significant reduction in local relapse 
with short-course and lead to the acceptance this course [5]. 
Swedish Rectal Cancer Trial showed that the rate of local 
relapse reduced from 27% to 11% (p˂0.001) and the survival 
rate in 5-year increased from 48% to 58% with neoadjuvant 
short-course radiotherapy and surgery arm compared 
surgery alone [5]. After 13 years of follow up experienced 
to continue the benefit for local relapse, overall survival and 
event free survival for short-course radiotherapy and surgery 
arm (26% to 9%; p:0.001, 38% to 30%; p:0.008, 72% to 
62%; p:0.03 respectively) [6]. The Dutch trial compared 
short-course radiotherapy and surgery as total mesorectal 
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excision alone [7]. This trial showed significant reduction 
in local relapse in short-course radiotherapy arm. Twelve 
years of follow up report confirms that the benefits for 
local relapse (11% to 5%, p<0.0001) incidence and overall 
survival with stage 3 cancer with a negative circumferential 
resection margin (50% to 40%, p:0.032) in short-course 
preoperative radiotherapy group [8]. 
The short-course radiotherapy is with acute toxicity 
included gastrointestinal symptoms or sacral pain occurred 
after 3-7 days after the completion of radiotherapy in about 
10% of patients [9]. 
Irradiated patients had with more bowel movements and 
fecal incontinence compared to nonirradiated patients in 
Swedish rectal cancer trial. Six months after treatment the 
short-course radiation arm patients had higher diagnosed 
with bowel obstruction. This late side effect can be associated 
with large radiotherapy portals (the upper border top of L2 
vertebrae) in this trial [10]. Increased incidence of small 
bowel obstruction was not confirmed by the Dutch TME trial. 
The Dutch TME trial showed that irradiated males had 
more ejaculation problems can be associated by irradiation 
seminal vesicles, erectile dysfunction can be related with 
damage of the small vessels [11].
Long-course neoadjuvant chemoradiotherapy
Short-course is commented in terms of does not give 
permission chemotherapy as concurrently. The Polish 
trial compared preoperative short-course radiotherapy and 
preoperative long-course chemoradiotherapy with randomized 
316 patients.  There were no significant differences in local 
relapse, sphincter preservation or survival rate. The rate of 
circumferential resection margin was higher in short-course 
radiation arm (4% to 13%, p:0.01) [12]. Another important 
trial TROG-0104 compared short-course radiotherapy and 
long-course preoperative chemoradiotherapy, after surgery 
the patients received adjuvant chemotherapy. There was no 
significance in local relapse, overall survival between two 
groups. But there was significance for increased T down 
staging in the long-course arm (p:0.003).  
There are a lot of randomized trials compared 
preoperative and postoperative chemoradiotherapy have 
shown significance for local control rates [13]. Long-course 
preoperative chemoradiotherapy has some advantage as 
allow systemic therapy concurrently, possibility of achieving 
down staging of the tumor, less acute toxicity, improved 
radio-sensitivity due to better oxygenated cells in contrast 
to postoperative era and higher sphincter preservation 
rates [14]. Recent literature has been reported that the rate 
complete response in patients 15-30% with long-course 
chemoradiotherapy. Complete response lead to better 
prognosis [15]. Rate of local relapse is effected by totally 
excision with negative circumferential resection margin and 
complete or good response may allow it. 
Preoperative chemoradiotherapy can downstage and 
improve resectability in unresectable tumors also with 
acceptable acute toxicity and event free survival. On the 
other hand distant metastases still observed 30% of patients. 
Braendengen M et al. compared preoperative chemoradiation 
as long-course plus 5FU/LV and long-course radiotherapy 
alone in unresectable or recurrent rectal cancer patients 
and described significance in local relapse reduction and 
event free survival in chemoradiotherapy arm [16]. Long-
course radiotherapy is given usually with 5FU, either as a 
continuous infusion in combination with leucovorin, or 
capecitabine, UFT. It is criticized that the chemotherapy 
used less than fully doses as concurrent chemoradiotherapy 
era, has no effect on survival. 
Oral capecitabine produced good clinical outcome in 
conjunction with neoadjuvant radiotherapy for locally 
advanced rectal cancer patients. Hofheinz et al showed the 
rate of ypCR (14%) was significantly more in capecitabine 
group (p=0.09) compared with fluorouracil [17].  
There is a phase II trial showed that neoadjuvant 
chronomodulated capecitabine and concurrent radiation 
therapy is effective and well tolerated with low toxicity 
profile [18]. This study reported excellent ypCR rate 
(20%), low rates of grade III diarrhea (10.5%), grade 3 
thrombocytopenia (only one patient), grade II or III proctitis 
(10.5%), hand and foot syndrome (3.3%). There were no 
grade IV toxicities. 
Comparison of the regimens
The Polish trial, one of the studies that compared between 
short-course radiotherapy and long-course chemoradiotherapy, 
reported no significance in survival, sphincter preserving 
and local relapse for 5 years follow-up. The Trans-Tasman 
Radiation Oncology Group (TROG 01.04) study also 
compared between short-course radiotherapy and long-course 
chemoradiotherapy, included adjuvant chemotherapy with 
5FU and folinic acid for 6 months in both arms. Median 
follow-up was 5.6 years. The results of this trial were similar 
for short-course and long-course in terms of local relapse 
(7.5% versus 5.7%), event free survival (67% versus 71%), 
overall survival (74% versus 70%) and late effects (7.6% 
versus 8.8%). The authors found both trials underpowered 
in terms of number of randomized patients to detect the 
significance between two regimens. Another conclusion that 
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quality of life documentation was poor in Polish study and this 
lead no significant difference between two arms. 
Stockholm trials reported significant higher in 
postoperative mortality, bone fractures, small bowel 
obstruction, fistulae and thromboembolism in short-course 
regimen. The Dutch TME study demonstrated that the 
higher rate of postoperative complications and secondary 
malignancy in short-course arm. Another important point 
from Dutch TME study that the rate of non-cancer related 
causes was higher in elderly patients (Table 1). 
Table I: Randomized trials of neoadjuvant treatment
Trial N pCR
Local
Recurrence
RFS/
DFS
OS
Swedish Rectal 
Cancer Trial (6)
RT + S
S
1168
9%
26%
13 years
38%
30%
Dutch Trial (8) (Stage III)
RT + S
S
1861
5.8%
11.3%
10 years
50%
40%
Polish Trial (10)
SCRT + S
CT/RT + S
316
1%
16%
9%
14%
4 years
58.4%
55.6%
4 years
67.2%
66.2%
TROG 01.04 (11)
SCRT + S
CT/RT + S
323
1%
15%
7.5%
5.7%
5 years
67%
71%
5 years
74%
70%
Istanbul R-01 Trial (20)
CT/RT + S (4w)
CT/RT + S (8w)
153
14.3%
19.7%
11.8%
10.3%
5 years
73.2%
74.2%
5 years
76.5%
74.2%
Reconstructions in short-course preoperative 
radiotherapy
Short-course radiotherapy is practical and useful choice but 
has high rate of postoperative complications and integration 
of chemotherapy resulted with intolerance. Traditionally 
after short-course radiotherapy performed surgery 
immediately. Achieving complete tumor regression with 
minimally morbidity is not easy in short-course. It seems 
that tumor regression after neoadjuvant therapy is related 
with the time elapsed between completion of neoadjuvant 
therapy and surgery.  A lot of studies support the idea that 
degree of tumor down staging is probably time-dependent 
[19]. Retrospective series reported short-course with a 
delayed surgery was associated with lower rates of acute 
toxicity [20,21]. Stockholm III study compared short-course 
radiotherapy followed by surgery within 1 or 4-8 weeks and 
long-course radiotherapy followed by surgery within 4-8 
weeks. Interim analysis was not reported any significance in 
acute toxicity [22].
 Faria et al. found that in phase II study, short-course 
followed by delayed surgery was feasible and had good 
tolerance. In this study all patients underwent total 
mesorectal excision surgery and had negative surgical 
margins, ypT0 rate was 10% [23]. Saglam et al. compare 
the efficacy of four-week versus eight-week delay before 
surgery. In this study 4-week and 8-week groups did not 
differ with regard to lateral surgical margin positivity 
(9.2% vs.5.1%, P=0.33, respectively), pathological tumor 
regression rate (P=0.90), overall survival (5-year, 76.5% 
vs. 74.2%, P=0.60) and local recurrence rate (11.8% vs. 
10.3%, 0.77) [24]. Based on these conclusions the Rectal 
Cancer and Preoperative Induction Therapy Followed by 
Dedicated Operation (RAPIDO) randomized trial compared 
short course followed by 6 courses of capecitabine plus 
oxaliplatin and fluoropyrimidine-based preoperative long-
course chemoradiotherapy before surgery [25]. There is a 
prospective randomized study continues compare a total dose 
of 3300 cGy in10 fractions with concurrent chemotherapy 
as capecitabine 825 mg/m2/BID delayed surgery and long-
course chemoradiotherapy delayed surgery by Hoon Lee et 
al [26]. This study reported very low toxicity profiles, very 
high rate of sphincter preservation (91.2%). In this study 
reported the rate of grade 3 hematologic toxicity 3.8%, grade 
3 postoperative complications such as ileus and wound 
dehiscence 2.5%. There was no grade 4 toxicity.
Trying to reduce the rate of radiation toxicity accelerated 
nowadays. Precise radiation techniques as intensity-
modulated radiotherapy (IMRT), volumetric-modulated arc 
therapy (VMAT) and proton therapy allow delivering high 
dose to tumor and low dose to normal tissue (Figure 1). 
 Reduced treatment-related toxicity and long survival 
time can be possible with the advent of new treatment 
techniques and schedules in locally advanced rectal cancer 
patients. Results from recruiting randomized trials will shed 
new light on these efforts.
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Figure1. IMRT allows to spare anterior pelvis partially and similar 
with 3 field technique but VMAT plan allows a limit dose to organ 
at risk
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